Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 0 | 1,322 | 2,239 | 23,904 | 60,876 |
| Gross Profit | N/A | 1,322 | 2,239 | 23,904 | 60,876 |
| Operating Expenses | 48,953 | 44,233 | 40,314 | 52,822 | 74,269 |
| Operating Income | -48,953 | -42,911 | -38,075 | -28,918 | -13,393 |
| Interest Expense | 241 | 318 | 315 | 302 | 295 |
| Other Income | 62,468 | 9,124 | -3,803 | 10,504 | -3,457 |
| Pre-tax Income | 13,274 | -34,105 | -42,194 | -18,715 | -17,145 |
| Income Tax | N/A | N/A | N/A | 26 | N/A |
| Net Income Continuous | 13,274 | -34,105 | -42,194 | -18,741 | -17,145 |
| Net Income | $13,274 | $-34,105 | $-42,194 | $-18,741 | $-17,145 |
| EPS Basic Total Ops | 0.22 | -3.68 | -7.64 | -4.31 | -6.30 |
| EPS Basic Continuous Ops | 0.69 | -3.68 | -7.64 | -4.31 | -6.27 |
| EPS Diluted Total Ops | -0.79 | -3.68 | -7.64 | -4.31 | -6.30 |
| EPS Diluted Continuous Ops | 0.22 | -3.68 | -7.64 | -4.31 | -6.27 |
| EPS Diluted Before Non-Recurring Items | -0.79 | -3.68 | -7.64 | -6.10 | -6.30 |
| EBITDA(a) | $-45,960 | $-38,355 | $-34,330 | $-25,626 | $-11,740 |